Omer Trivizki - research works

Ninety-four studies met inclusion criteria, spanning spectral-domain and swept-source OCT platforms and diverse AMD phenotypes.

Structure-function analyses demonstrated moderate-to-strong correlations between photoreceptor loss and microperimetry sensitivity ( r = 0.50-0.80) and best-corrected visual acuity ( r = 0.40-0.70), particularly in advanced disease stages.

A total of 55 patients with mMNV, with a mean age of 65.7 ± 14.5 years, met the inclusion criteria.

The mean number of injections was significantly higher during the first year of follow-up with 8.78 ± 2.90 within the 1st year versus 3.45 ± 4.40 during the 2nd year (p = 0.037).

Visual acuity (VA) remained relatively stable throughout the follow-up (p = 0.902), with most patients maintaining their vision or experiencing a loss of up to 5 Snellen letters.

A total of 263 eyes of 263 patients with a mean age of 71.5 ± 11.2 years of which 50% were of male gender met the inclusion criteria.

There was not a significant difference in mean age (p = 0.634) and gender (p = 0.269) between the groups.

The difference between the rate of change in BCVA per year was insignificant between groups (p = 0.414).

In multivariate analysis, baseline BCVA was the single significant predictor for switch (beta 0.137, p = 0.035).

During the COVID-19 period, the mean number of anti-VEGF injections was significantly lower than the corresponding pre-COVID-19 and post-COVID-19 periods (5.55 compared to 6.13 and 6.60, respectively p < 0.01).

Baseline BCVA (0.825, p < 0.001), number of injections (-0.007, p < 0.001), gender (-0.027, p = 0.037) and age (0.004, p < 0.001) were shown to be significant predictors of final BCVA.

Baseline best corrected visual acuity (BCVA) among patients in 2019 and 2020 was 0.52 ± 0.44, 0.45 ± 0.43 (logarithm of the minimal angle of resolution, respectively).

There was no significant difference between the years 2020 and 2019 in baseline BCVA (p = 0.07).

Baseline BCVA (p < 0.01) was the only significant predictor of final BCVA.

Number of injections, age, gender, and the year were not found as predictors of final BCVA.